Informations générales (source: ClinicalTrials.gov)
Identification of Biomarkers Associated With the Presence of Malignant Pancreatic Lesions Compared to Benign Lesions.
Interventional
N/A
Centre Hospitalier Universitaire de Besancon (Voir sur ClinicalTrials)
décembre 2024
juin 2027
18 septembre 2025
The challenge for medical oncology is to develop plasma biomarkers that can detect the
influence of the stroma on diagnosis, prognosis and response to chemotherapy.
Today, there is no validated blood test to help diagnose pancreatic cancer (PDAC). The
search for blood biomarkers of the tumor stroma and immunological markers is therefore a
major challenge in orienting the diagnosis towards PDAC and optimizing the therapeutic
management of pancreatic cancers.
The aim of the study is to identify biomarkers associated with the presence of malignant
pancreatic lesions (patients from the Pancreas-CGE cohort, a cohort already set up by our
team) compared with benign lesions (patients followed up for benign pancreatic lesions).
Candidate biomarkers from our preliminary work will be considered initially. Other
biomarkers may be explored secondarily.
The ultimate goal is to develop a clinico-biological signature that is as efficient as
possible in predicting the presence of malignant pancreatic lesions compared with benign
ones.
Etablissements
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| Hôpital Nord Franche-Comté - Montbéliard - France | Contact (sur clinicalTrials) | ||||
| University Hospital of Besancon - Besançon - France | Angélique VIENOT, Dr | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- Men and women ≥18 years
- Patient followed for benign pancreatic lesions:
chronic pancreatitis acute pancreatitis at a distance from the acute episode (> 4 weeks)
with indication for echo-endoscopy for suspected precancerous pancreatic lesions (PanIN,
TIPMP, mucinous cystadenomas) or other cystic lesions (serous cystadenomas)
- Men and women ≥18 years
- Patient followed for benign pancreatic lesions:
chronic pancreatitis acute pancreatitis at a distance from the acute episode (> 4 weeks)
with indication for echo-endoscopy for suspected precancerous pancreatic lesions (PanIN,
TIPMP, mucinous cystadenomas) or other cystic lesions (serous cystadenomas)
- Malignant pancreatic tumor
- Legal incapacity or limited legal capacity